Request Trial
istock-839222794-nicoelnino
NicoElnino / iStockphoto.com
15 May 2018Americas

Eli Lilly to acquire cancer drug developer

Eli Lilly has revealed plans to acquire Montreal-based AurKa Pharma, in what is the company’s second acquisition in less than one week.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’
10 February 2026   Telehealth platform faces legal action from the Danish pharma giant, as well as FDA pressure over GLP-1 drugs and a drop in shares after discontinuing new product.
Americas
Novartis takes aim at Tafinlar generic in latest suit
9 February 2026   The Swiss pharma giant moves to protect patents on its billion-dollar cancer therapy following an ANDA filing by a Canadian generics manufacturer.
Americas
Semaglutide patent battle heats up with new blow for Novo in India
6 February 2026   A Delhi High Court ruling signals more bad news for the Danish pharma giant in the same week that it lost nearly $50 billion in value.


Editor's picks

Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’
Americas
Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’
10 February 2026

Editor's picks

Americas
Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’
10 February 2026
Americas
The quantum advantage: IP considerations for the next generation of life sciences innovation
27 January 2026
Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026
Americas
Bayer enters COVID-19 vaccine row with three suits against major drugmakers
8 January 2026
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025
Europe
Abbott appeals ‘baffling’ decision in glucose monitoring device feud
16 December 2025

More features

Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’
Novartis takes aim at Tafinlar generic in latest suit
Semaglutide patent battle heats up with new blow for Novo in India
Wilson Sonsini senior counsel moves to a rival firm
AstraZeneca partners with Chinese firm ahead of next obesity race
INTA: ‘Davos of IP’ will take London meeting to a ‘different level’
Nine-partner litigation team leaves Winston & Strawn
Squire Patton Boggs brings in tech and data expert as Ireland practice lead